Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning everybody and welcome to Terveystalo Q4 and Full Year 2025 results call and webcast; as usual, we will go through the results with CEO Ville Iho and our CFO Juuso Pajunen, and will follow that with the Q&A; my name is Kati Kaksonen, I am responsible for investor relations and sustainability here at Terveystalo; we will take the questions via the phone lines first and then follow with questions. Via the webcast at the end of the presentation. Without further ado, over to you, Ville.
Thanks Kati and good morning from cold and beautiful Helsinki. Let's dive into it. Terveystalo. Results. 2025, it's again time to take a couple of steps back and look at how we performed last year. Short of the big headline, here is profitability and efficiency if one looks at our financial performance. We are delivering all-time high profitability, and as you can see, it is leading across all segments, which are improving. Things are great if one looks at the quality of our services, things are great; on the other hand, of course, you can see that we are living in a market which is not favorable, but that only underlines the efficiency of our operational and financial steering, allowing us to produce robust results even during headwinds; healthcare services is a post-cyclical industry, and now we can see in our services a decline in the frequency of use, even though the number of customers during the year was the same as during twenty twenty-four, but with strong financials. Declining revenue due to macroeconomic and post-cyclical nature of our business, yet with very strong improving quality. Double-clicking into the performance of our three different business areas – healthcare services improving with declining revenue, portfolio businesses improving with declining revenue, and Sweden improving with declining revenue – all of these underline the same story: the market is difficult, but we have been able, through our actions, to improve operating leverage and efficiency, improve our margins, and as you can see from a longer trend, clearly achieve the best results ever produced by Terveystalo. Thanks to dedicated focused work in our operations. Given the circumstances, the focus of our actions, of course, shifted more and more towards customer and growth as key priorities. The agenda stays intact, we concentrate on healthcare services. Of course, still in digital transformation. Getting ever more efficiency and productivity into our processes, but as I said, with more focus on customer value, we are generating growth through all of the segments; consumers, Kela 65, and insurance customers are focus areas. We are gaining ground in occupational health care. We are investing heavily in renewing our product and services. We have a two-year program started last year, and we will invest ten million euros in the product and services and renew those, and once the market turns, of course. We are stronger than ever in portfolio businesses. We have said that we will fix the profitability, and then we step into growth, and from the results you can see that we have delivered the profitability turnaround, and as you saw from our actions before year-end, we signed the deal on the acquisition of Hohde in dental services. So we are really delivering growth as well; going forward, we are investing into that one; Sweden, a similar kind of story. Through our program, we have fixed the profitability. Olemme tyytyväisiä tuloksiin. Vaikeasta markkinasta huolimatta olemme parantaneet kannattavuutta, ja nyt olemme valmiita investoimaan ja kasvattamaan myös tätä liiketoiminnan osaa. The Hohde deal is a major milestone for portfolio businesses and specifically for dental, as per our earlier commitment. We said that dental is part of our core offering, and we will invest in that one, grow that one, and double the business while doubling the profitability; this is a major milestone in that journey, not surprising but a very logical one, as the joint combination of Terveystalo Dental and Hohde will be a really strong and high-quality player, generating ever more value for our customers—for corporate customers and consumer customers alike—and we are of course very excited and proud of this step. We have been leading digital transformation in outpatient care for quite some time, and we continue on that journey; if one looks at this transformation in a little bit more structured way, we can distinguish three different modalities that we continue investing in. So, we have more traditional hybrid integrated care continuum, which is still going to be our focus and lead, and there we invest in better integration, higher efficiency, better toolkit for our professionals, and better customer experience and patient experience for all customers. There we have just launched a major new UI platform for professionals, called Ella, so that's our professional interface whereby they are able to process appointments and manage other general operations. Ella-alusta varmistaa jatkuvasti korkean laadun ja tehokkuuden. Much of the information and data is more structured and presented in steps. Loogista ja läpinäkyvää, kun potilas siirtyy askeleelta toiselle jatkuvassa hoidossa. This will be further enhanced. This Ella platform will be scaled during this year, but we can already see tangible results after its mid-year launch. We are talking about algorithm-led digital health and retail modality, where automation and a very low-click type of operation are key; so, when you enter into our services through a web app, you engage with the automated AI-assisted and pace-based steering engine, which then steers you to a traditional modality or to digital appointments – either to a more traditional type of service, which we will make more and more efficient, or to the recently launched semi-automated AI-assisted appointment modality, where the target is that the whole appointment chain can be processed by a professional with a single click at the end of the development phase; this is a really fast, highly available service area which we will further invest in, as we have a fast development pace in this area; and the final domain in the transformation, where investments yield results, is insight-centric proactive care, with Medhelp AP platform as the best example in our implementations. Nyt esittelemme Medhelp AP -alustan, jonka otamme käyttöön Q1:n aikana työterveysasiakkaille tarjoten älykkäitä oivalluksia. Clever use of data, activation of patients and customers in right time situations, and making a major step from reactive. Traditional healthcare modality into proactive, insight-driven. Semi-automatisoitu ajanvaraus on erittäin jännittävää, ja se lanseerattiin vain pari viikkoa sitten; tämä uusi ajanvarausketju potilaan näkökulmasta toimii niin, että kuten sanoin, palveluihin tullaan tyypillisesti sovelluksen kautta, minkä jälkeen ollaan yhteydessä tekoälyavusteiseen älykkääseen ohjausmoottoriin, joka sitten ohjaa sinua, jos diagnoosiskenaario on relevantti, tekoälyavusteiseen ajanvarausketjuun, jossa itse asiassa kehityksen lopussa, kun kehitämme tätä edelleen tämän vuoden aikana, ammattilainen pystyy hyväksymään diagnoosit yhdellä klikkauksella, ja sitten saat diagnoosisi. Saat ohjeistuksen tehdäksesi oikeat toimenpiteet diagnoosin tai hoidon päätteeksi, mikä on todella jännittävää ja täydentää jo entisestään tehokasta digitaalista alustaamme, tarjoten meille suunnan tulevaisuuteen ja edelleen potentiaalia parempaan asiakasarvoon, palveluiden korkeaan saatavuuteen ja samanaikaisesti korkeaan tehokkuuteen sekä kannattavuuteen, ja täten vuoro siirtyy Juusolle.
Thank you, Ville. Let's talk about our financial performance. Obviously, as already on the reports. It's all in the reports; you know the numbers by heart. So, let's start actually from the journey three years ago; I was standing here for the first time presenting quarterly results of Q4 2022, and at that point in time, we had an annual EBITDA percentage of 8.4 percent, and we were brave when we said that by 2025. Saavutamme 12 prosenttia, mutta itse asiassa saavutimme sen jo vuotta etuajassa, saavuttaen 12 prosenttia vuonna 2024, ja tänä vuonna 2025 toimitamme 14 prosenttia, ja nyt kaikki, mitä näette näissä luvuissa. What comes to efficiency, it signals and proves that point that we have made a sustainable, strong change in our operating model, and we are as efficient as one can be, also with Ville's description of the one-click customer journey. On the customer journey, we can still improve our efficiency further. We are today in Q4. We are in all efficiency metrics. Strong, we have improved our EBIT, we have improved our margins, we have improved our EPS; we have not done that at the cost of our client satisfaction. Our NPS is at 7.6, which is extremely strong. Our medical quality indicator PEI is at an all-time high also, so we are efficient, we are impactful, and we are delivering financials, but at the same time. On kuitenkin syytä todeta, että meillä on liikevaihdon vastatuulia. Käydään nämä asiat hieman tarkemmin läpi, kun siirrymme segmenttitasolle, ja katsotaan samalla Q4:n yleiset kohokohdat. We are strong, we are efficient, but we have market headwinds, and we will address those. Jos tarkastelemme koko konsernia, meillä on positiivinen marginaalikehitys, kuten selitettiin. Our strength is especially in our efficiency metrics. Revenue was under pressure in all segments, and we will review them at the segment level. What we have in the megatrends are the basics for our trends. We have the outsourcing portfolio. Meillä on työterveys. Vaikutukset ja yhdistetyt asiakkaat. Eli kaikki tuo on oikeastaan jatkumoa jo Q3:lta, sitten kun tarkastelemme oikaisueriä. We had 0.7 million euros. It is good to understand that the majority of these ones are related to our own efficiency actions on our ongoing projects, where we have taken an extra push in Q4, and a material part of those ones are consulting fees that are based on success, so they wouldn't be here unless we had been successful. And, of course, the consulting assignments are now especially in Sweden and material parts, and we are in a positive place on that one. Then, on top of that one, we had write-offs related to divestment of childcare services that one has actually now closed in First of February. So it will be totally out from our numbers. Starting first of February 2026 onwards, that is non-cash. Arvonalennus, ja sen lisäksi meillä oli verokiista, ja nämä kaikki olivat kertaluonteisia eriä. Pushing our reported EBIT a bit lower, but still, that metric is in a strong place. If we then go deeper and look at healthcare services, this is what we find. Clear annual margin improvement. Margin improvement also strong, but we have headwinds in the revenues; visits are seven point six percent down when adjusted for the one working day more in the financial calendar, and then we have other impacts slightly positive, but all in all, the revenue is five percent down. We will go a bit deeper into the drivers and the volume growth in the following slide, but all in all, we have a strong plan, but we are also a post-cyclical company, operating by industry logic. So, we are just now under pressure, but with the efficiency that we have in our platform. We will turn this one around and with all of the actions we have in place and the underlying megatrends have not gone anywhere. Tämä on luonteeltaan kausiluonteista ja makrovetoista, koska olemme jälkisyklinen yritys. The trends are continuing. We can split it now into different buckets. We have the seasonality. This is roughly seventy thousand cases of upper respiratory infections during the quarter, and that has now continued in January again in February, showing the current flu season's impacts, and that contributes a certain amount. Emme voi vaikuttaa siihen, se tulee ja menee; sen sijaan makrotalouden tasolla, mikä periaatteessa tarkoittaa, että prosyklisenä yhtiönä makrotalous vaikuttaa meihin myöhemmin: jatkuvassa hitaassa makrotaloudellisessa ympäristössä yritykset yleensä investoivat vähemmän henkilöstöönsä, mutta se on viimeinen paikka, josta investointeja halutaan leikata. That's why it hits us a bit later than in some other industries, and that one we can work on, we can concentrate on client value. We can concentrate on delivering the highest possible impact with an efficient model, but we cannot hide away the fact that many companies are starting to reduce their investments at some point in time. It also impacts us, but we have a clear action plan both on how we capture back the growth regardless of the macroeconomic environment, and then how we utilize our efficient model when we capture that growth, so we are in a positive place in that one from a plan perspective, and we are confident that we deliver on that one. The public sector, remembering that we talk about healthcare services, has now been. Kapasiteettimyynti on pieni osa kokonaistarjoamasta, ja se on ollut pitkään heikossa asemassa hyvinvointialueiden vuoksi, jotka ovat ensin keskittyneet perustamiseen ja sitten kustannusten jahtaamiseen, mutta nyt ympäristö alkaa vähitellen vakiintua, ja olemme nähneet joitakin positiivisia signaaleja, mutta samanaikaisesti. Se on edelleen melko ennustamaton markkina, josta kerron tarkemmin tulevalla dialla, ja sitten meillä on positiivinen momentti kuluttajilta; meillä on sekä vakuutusmarkkinat, joilla vakuutettujen määrä kasvaa hitaasti, että meillä on täällä vahva markkina-asema ja erittäin arvostettu tarjooma vakuutusyhtiöille, ja Kela 65 -pilotti on tuottanut positiivista volyymikasvua ja jatkaa positiivisen volyymikasvun tuottamista vuodelle 2026. Eli kaiken kaikkiaan. We know what is happening, we have our action plan and we will deliver according to that action plan, then if we look. Portfolio businesses, we have a clear profitability improvement that has continued. It's also good to acknowledge that the previous year, Q4, was a difficult one, and now we are obviously clearly improving on that; the revenue was contracting because of the outsourcing contract, according to plan, so it's good to know that we have been very solid in steering and running those contracts, and they have now started to deliver also profits which have contributed to Q4 results, particularly in staffing. Tämä trendi johtuu edelleen osittain omista valinnoistamme. Earlier, but at the same time, the market continues to be difficult. We have seen some positives in the total market environment and we have been gaining market, but wellbeing services are still in the cycle. We are evaluating how they operate in the future; dental and private continued to be the positive part of the story. We have been able to grow the top line, grow the bottom line, and we are trending in the right direction, and then you have seen our investment in Hohde. If we look on Sweden, the market continues to be difficult. It's good to know that the operational efficiencies are improving, and we are ramping up our EBITDA percentages. Our EBITDA percentages slightly declined; this occurred alongside a non-cash related impairment item that was actually a positive impairment from previous year Q4, so all in all, we are in plan. We are delivering; we are bringing the efficiency up that we have established, and now we are in a place where we can start utilizing this platform also in an efficient manner and start ramping up the revenues and the pipeline. The pipeline is strong for the future. Olemme siis luottavaisia Ruotsin suhteen, mutta luonnollisesti markkinaolosuhteet ja työllisyystasot ovat edelleen haasteena myös Ruotsin markkinoilla. If we then go about investments. I think that what is happening here is exactly what we have told: we have said that we are ramping up our investment in digital and are also doing physical investments on the digital part; Ville explained about Ella and the one-click journey, with those being a couple of the highlights; and the Medhelp cooperation that we launched last year in the second half is now starting to deliver actual output in Q1 2026. So, what is important to note is that when we make an investment, the investment cycle is fairly short from the start of the investment to the actual use of the digital asset, as demonstrated by Ella. Ella on ammattilaisten käyttöliittymä, joka on jo satojen lääkäreiden käytössä, ja seuraavat vaiheen käyttöönotot tapahtuvat parhaillaan. Medhelp, olemme nyt tilanteessa, jossa olemme alkaneet esitellä sitä asiakkaillemme ja olemme ensimmäisissä käyttöönotoissa Q1:llä. So also this one is progressing. Se ei ole pelkkä lupaus tulevaisuuteen. It is an action today, and that one we will continue. We will continue to invest in both organic and inorganic growth for the future, and now with M&A. Yrityskauppojen osalta meillä on ollut Hohde-kauppa ja pari pientä täydentävää yrityskauppaa, ja keskittymisen osalta luovuimme vähäkassavirtaisesta lastensuojeluliiketoiminnasta. I have nothing new to say on this topic. What has been repeated for the past two quarters is that we continue to deliver cash; whatever we do on the bottom line, we do in the bank accounts. Also, the total net seven million cash flow was slightly soft due to a timing component on the accounts payables, as the last day of the year was a banking day and we are responsible for monitoring our vendors – most of whom, like us, are small – and we pay on due dates, delaying those payments by one day. We would have actually made visible changes to this number, but that's not how we operate. Leverage 2.1 continues to be an all-time low, so when we want to invest, we can invest. Meillä on liikkumavaraa velkasuhteissamme, ja jälleen viitaten Hohde-yritysostoon, se on kilpailuviranomaisen hyväksynnän alainen eikä siksi ole vielä näkyvissä velkasuhteessa. Once competition authority approval is obtained, we will finalize the acquisition and hand over the money to the sellers. Looking back. On our financial targets. We have three targets: EPS growth, ten percent per year. We also told that 2025 will be clearly better than the 10 percent, with EPS now at 0.73, up 29 percent net; Net Debt to EBITDA being below 2.5, but can deviate during certain periods of the year. We are 2.1, and then for attractive dividends, at least 80 percent of the net results: 64 cents proposed by the Board of Directors, meaning 80 percent of the net profits as a total and a 33 percent handsome growth on the dividend for the year, assuming of course that the AGM approves it. And so, we do what we promise to do; we have delivered on each of these metrics once again, before going into the guidance. It is good to have a few words on the demand environment when we talk about this picture. What we are saying is that the demand environment is anticipated to improve gradually by the end of 2026. The 2025 rows describe where we are starting the journey this year, and the 2026 rows describe where we expect to land at the end of this year. So what is happening now is that if we look at the public sector, it is yellow. We have continuous modest positives. We have some big ones, we do know that there are some big ones in the tender pipeline, there was one that. Pihlajalinna won one in four. Viime vuonna, mutta samalla ennustettavuus on melko matala hyvinvointialueiden osalta, ja niiden polarisoituminen sekä se, kuinka ne alkavat käyttäytyä, on aina ollut vaikeaa ennustaa, ja tästä syystä olemme keltaisella alueella. Tässäkin kuitenkin minun täytyy korostaa, että siellä on paljon myönteisiä heikkoja signaaleja, jotka voisivat tuoda lisää positiivista tulevaisuudessa; kuluttajamarkkinalla meillä on erittäin positiivinen tilanne, ehkä hieman enemmän hammashoidossa, ja koko kuluttajamarkkinalla vuodelle 2026. We are still positive; this is mainly due to the Kela 65 and related insurance. It is a market where insurance penetration slightly grows; still, at the same time, insurance companies. Getting better and better on steering their customers and impacting the market. So it is a positive market, but at the same time, last time the dynamics was the dark green arrow pointing upwards, so we think that that momentum is not as strong as it was earlier. What comes to occupational health. We have a strong plan, we had a difficult 2025. We are addressing all of our issues, we are confident and we are getting into growth, but now the market will remain challenged during 2026 in total and Sweden. We are seeing that improvement for 2026 is in the pipeline, so with this type of market dynamics. We come to our guidance for 2026. Our guidance for 2026 is 135 million to 165 million of adjusted EBIT; 2025's adjusted EBIT was 156 million. So basically, we are guiding a corridor where we have room to improve, but also based on the market conditions. We can be weaker this year; the estimates are basically built on a gradually improving market environment or demand environment. We know as a fact that first half upper respiratory diseases will be clearly below the previous year. You have seen how it behaved. You can go to see our open data sources to see how January, February up to week seven have been behaving or up to week six at the moment has been behaving. So we know as a fact that it will be a difficult flu season for the first half of the year, and then we are expecting for the second half normalization. So with all of that, it means that our first half will be below 2025 due to the market environment. Ylähengitystieinfektioiden vuoksi, mutta kun etenemme, näemme vähitellen parantuvia markkinoita, portfolio-liiketoimintojen liikevaihdon jatkaessa pienenemistään noin kahdellakymmenellä miljoonalla eurolla vuositasolla, ja lopuksi ohjeistuksemme ei sisällä merkittäviä yritysostoja, kuten Hohde-kauppaa, emmekä tiedä milloin se sulkeutuu, eikä sitä ole sisällytetty näihin lukuihin. Kaiken kaikkiaan. I think we are going for a solid 2026 in absolute terms. But of course in relative terms. There are also scenarios where we can be weaker than 2025. Let's invite Kathy back on to the stage and let's start the Q&A.
Kiitos Juuso, minusta olemme nyt valmiita kysymyksiin. Onko meillä kysymyksiä puhelinlinjoilta?
Jos haluat esittää kysymyksen, paina puhelinnäppäimistöltä näppäintä viisi päästäksesi kysymysjonoon; jos haluat peruuttaa kysymyksesi, paina näppäintä kuusi. On your telephone keypad. The next question comes from Sarkamies from Danske Bank Markets. Please go ahead.
Hi. I have a couple of questions and will take them one by one. Firstly, regarding the outlook for this year, my first question would be why you expect the first half to be down from last year in terms of profits. I guess market conditions were broadly difficult already in the second half last year, but we didn't see profitability falling below the comparable period. So why is the first half more challenging than the second half last year?
Eli, verrattuna edellisen vuoden alkuun ja täydentäen asiaa, jos katsomme nykyistä tilannetta, tiedämme, että ylähengitystieinfektiot ovat selvästi alle Q1 2025:n. Mikä oli selvästi keskimääräistä korkeampi, joten tällä hetkellä hengitystieinfektioiden määrä on jo selvästi nähtävissä, ja se on yksi vastatuuli; sitten toinen tekijä on se, että jos katsomme yritysasiakkaiden työntekijöiden ja työnantajien käyttäytymistä, yritysasiakkaiden työntekijöiden käyntimäärät ovat edelleen nelisen prosenttia alemmat verrattuna Q1 2025:een, ja tämä osaltaan vaikuttaa Q1:n vaikeuksiin; ja sitten nykyinen makrotaloudellinen ympäristö ainakaan tammikuun osalta ei ole merkittävästi parantunut viime vuoden Q4:stä. So the employers are still clearly in the cost-saving mode, so with all of these and against a very strong first half in 2025. This is our expectation that from an EBIT perspective. We will be below the previous year.
And then all I would add is, to sum up all the dynamics in the market. What we see today is that the frequency of use of the services is down basically in all of the segments, so that is the main contributing factor. It's a cyclical and then it's a sort of upper respiratory morbidity type of impact, and it will of course turn around, but what we see today in the market is a negative impact, especially against Q1 last year.
And my second question regarding outlook would be, can you elaborate on the key uncertainties, because we are looking at a broadly wide guidance range for this year?
Yes, so basically, when we look at the guidance and its parameters, the one component is a gradually improving demand environment. So the different types of variables are what is the macroeconomic outlook, what will be the status of Finland and obviously also Sweden's economy. How the employment behaves and how that impacts on the employers' behavior? So that is one component, and the consumer purchase power is the second component, which is relevant for use in our private out-of-pocket segments. So there are different types of scenarios available regarding the positive momentum. Kuten tiedätte, olemme noin kahdenkymmenen prosentin EBITDA-yhtiö. Voimme hyödyntää positiivista momentumia erittäin voimakkaasti, mutta myös jos nykyinen trendi ja laimea talousympäristö jatkuu, se haastaa myös meitä. So this is the clear external component, then the second one is the seasonality related to upper respiratory diseases that one obviously nobody knows how next August starts and how that one behaves in real life, so the only way to predict is assuming regression to the mean.
Juuso, haluatko vielä lisätä? If one looks at this as being a little bit negative on Q4, if one turns that around, once the revenue and frequency of use of services come back, given that operating leverage and efficiency are on such a high level, then of course, it will really yield results, but as a short, very simple answer. It is the demand, specifically the frequency of use of services, which is the key. It is the number one, but that will then dictate on which end of the spectrum we will end in our guidance.
So the lower end of the guidance range would assume basically no recovery in the Finnish macro environment, with consumers not consuming, and then, say, a weak flu season during the second half of this year.
Okei.
Okei, sitten mainitsit, että teillä on edelleen tällä hetkellä alempi määrä kytkettyjä työntekijöitä. I think that was also the case six months ago, so there's been no progress on that front; can you elaborate on why you haven't been able to improve your market position, even though that has broadly been one of the key targets?
If I start. Sanoisin, että ensinnäkin, kuten sanoin, on olemassa kahden vuoden ohjelma, jossa investoimme kaksikymmentä miljoonaa tuotteisiin ja palveluihin, ja edistymme hyvin tässä ohjelmassa. Täytyy ymmärtää dynamiikkaa siitä, miten yritykset tekevät päätöksiä ja kuinka pitkiä nuo prosessit ovat. Joten vaikka operatiiviset ja kaupalliset toimet sekä tuotteemme on osittain päivitetty, osittain jo uusittu. It takes some time and until we can see that, first and foremost, in connected employees' use of services and profitability in that segment, but I am really most pleased with how our new team is now taking the challenge and pushing us forward. We have tangible things that we have already been able to deliver to our customers, and with good response, during Q1 we will have a show of. Best in the industry platform delivered to our customers in occupational health care. We have been able to rectify past issues that were difficult from many angles; we had building issues, etc. etc. We have been able to rectify those, and with all of these soft points. We are or will be very soon clearly the market leader, and overtime the demand will be there.
When we want to touch upon one-off adjustments, you had in Q4 thirty million euros. I think you're not supposed to have this anymore. After the completion of the Alfa program, I understand that it is mostly related to Sweden, which does not generate any results at the moment. So can you elaborate on what kind of return on investment. We will see this year if you are paid about ten million as a kind of consulting success fee related to Sweden.
Let's first correct that Sweden is by far not ten million on that one; you will actually also see the adjustment items per segment on the final page of the report. We have three point five million euros in Sweden for Q4 and five point six million for the full 2025. So, just to be clear on the numbers. We have a cost component in Sweden; we incurred extra expenses that included roughly the employees in the admin part. We have digitalized, centralized, and taken a huge leap in the admin part in Sweden, and that has yielded what we call a success fee component and a restructuring component that was above our expectation, but that one will also basically improve our competitive advantage and competitiveness in the market and make us very efficient on that one, so I think that is money well spent when we show that we can make money in Sweden. Then, for Sweden to reach its full potential, it. Se edellyttää myös positiivista liikevaihdon kehitystä, mikä on ehdottomasti tarpeen täyden potentiaalin saavuttamiseksi. Sitten jos tarkastelemme muita oikaisueriä, meillä on arvonalennus lastensuojelun divestointiin liittyen, noin neljä miljoonaa euroa, ja meillä oli veroerä, joka on noin kahden miljoonan euron suuruinen. Tämä veroerä on näkyvissä tuloslaskelmassa ylempänä, koska se on kirjattu liiketoiminnan kuluna kannattavuuteemme. Kun Ruotsi-ohjelma on päättynyt, meillä on pienempiä ohjelmia, jotka jatkuvat portfolioissa, ja sitten meillä on Ville Iho:n ohjelma. Ville on maininnut jatkuvan ohjelman työterveyden kilpailukyvystä, joka on työterveysohjelma. We have been talking about this in Q3, or actually, already after the Q2 release, and that program will continue; it is the only worth mentioning program we are taking into 2026 and 2027.
Okei, kiitos selvennyksistä. Viimeiset kysymykseni koskisivat osinkoehdotusta, jolla nostetaan payout-suhdetta. Ratio from 80 percent to 84 percent, even though you may be looking at a down year when it comes to earnings. What is the logic here, because you are also doing M&A, so why are you upping the payout ratio?
Eli katsotaanpa nyt lukuja, niin ensinnäkin olemme pohjimmiltamme luottavaisia vuoden 2026 suhteen. We are confident for our future. Meillä on hyvin tasapainoinen tilanne, joka on selvästi alle velkaviputavoitteemme, vaikka Hohde-yrityskauppa olisi toteutunut jo tämän vuoden tammikuun ensimmäisenä päivänä. So, first of all, we have the capability to do so, and we have one of our financial targets as an attractive dividend to our owners; it doesn't limit our growth opportunities, and at the same time, if you look at child welfare. It is accounting-wise negative, but cash flow-wise positive, and if you calculate from there. Mielestäni kahdeksan prosenttia on täysin perusteltua.
Ehkäpä vain täydentääkseni mitä Juuso sanoi luottamuksesta, nyt kun puhumme, niin markkinoilla on vastatuulta. One is to remember that underlying megatrends in our business, combined with the efficiency that we have been able to build into the machine over time, will generate improving profits, and this is one year in a chain of years with a positive outlook.
Okei, thank you very much for the questions.
The next question comes from Anssi Räisänen from ACB. Please go ahead.
Yes, thank you for the presentation. I have questions left, and I'd like to continue with a question about the outlook for 2026. We have been discussing your operational improvement for Twenty twenty five. Twenty twenty five and your Q4 Adjusted EBIT and Adjusted EBITA quite significantly year over year. So then, when we think about 2026 and your comment about the improving market towards the end of the year. So is the missing piece here pricing, or because of course, you have been talking about defending or gaining volumes in 2026 and that being maybe the most important focus area?
Eli ehkä jos aloitan, nykyinen markkinaympäristö ei ole sellainen, että hinnoittelu tai suuret hinnankorotukset olisivat aiheena työkaluissamme, joten kilpailuympäristö on sellainen, että hinnoittelu on selkeästi eri tilanteessa verrattuna vuosiin 2023–2024, jolloin meillä oli myös korkean inflaation tai inflaation jälkeinen ympäristö, joten kuten olettekin narratiivissanne todenneet, tämä on eräänlainen puuttuva palanen kokonaisuudessa, sitten mitä tulee uuteen vuositason parannukseen. It's good to know that in Q4 of the previous year. We had the one-time bonuses that we paid to all employees, we had the additional collective labor agreement component also coming to all employees, so our Q4 for 2024 was not in a way as weak as it looked like from the outset. So, if we take an operational performance, we had a strong performance in Q4 2025, but you should not take just a comparison of Q4 2024 to Q4 2025 without taking that mental adjustment; then you see that we did not take any more that significant leap as the numbers indicate.
Maybe just to add on that, so the volume remains to be the key component. In the first half, we are not going to be seeing improving numbers in the volumes because of the reasons that we already discussed. So, increasing the connected employees within occupational healthcare will take some time that will not be visible in the first Q1, especially, and then we have other volume drivers at the moment going against us, but we do expect those trends, especially the connected employees, to gradually increase towards the end of the year, so that's the operating leverage driver.
That's good clarification; perhaps you could continue on diagnostics, where volumes declined. I think it was almost 12 percent in Q4, which is clearly more than the number of physical appointments, so of course you mentioned your customers being in savings mode maybe right now, but is this only due to occupational healthcare customers. Downgrading their service packages or is there also something else relating to your own operations?
Se on osa teidän mainitsemaanne vastausta, sitten diagnostiikkamiksin logiikka, kun meiltä puuttuu tietty osa ylempien hengitysteiden diagnooseista, ja esimerkiksi magneettikuvaukset ovat vähentyneet, niin tähän on selkeät loogiset selitykset. Katsottaessa palvelutarpeiden taloudellisia näkökohtia, jotka vaikuttavat volyymeihin diagnostiikassa.
If I fully capture your number logic, just a reminder that we were basically 7.6 percent down on a workday-adjusted basis. And even if you take into account that workdays were 1.6 percent positive, so we are about 6 percent down in volume, our revenues are 5 percent down. So actually, we have a positive pricing/mix component in healthcare services. Then, if we look at the total group revenues and you compare that to the visits, then you are kind of combining two different topics that are not fully in sync in total in the total group numbers. We have the reduction in staffing, which is not visit related, and the reduction in outsourcing business, which is not visit related. Then we have the reduction in Sweden, where we don't report visit numbers, so you need to be a bit careful when you're taking those comparisons.
Okei, joo. Pelkästään diagnostiikan määriä Q4:llä tarkastellen, vuosi vuodelta.
No okei, joo.
That I think was you, but that's clear, and maybe a final question. A simple one on your guidance, as you guide on EBIT: could you give us an assumption how depreciation and especially amortization will develop in 2026 compared to 2025?
Basically, we look on amortization. Obviously, we don't guide these numbers, but if I hint you on the mathematics, you can go to the balance sheet. You have seen that we have increased our investments, especially in digital items. Those ones will gradually hit the amortization in the income statement in the coming years. So, you can fairly easily take the notes and you can see there the increases, decreases, and you can from there deduct, but obviously, an increased investment base will mean at some point in time increased amortizations.
Google Drive to save some Excel time. Thank you, that's all from me.
Let's take it offline. I can show you some Excel skills.
As a reminder, if you wish to ask a question, please do pound key five on your telephone keypad. The next questions come from Joonas Sandholm from Nordea. Please go ahead.
Yeah, thanks; regarding a couple of remaining questions, my question, perhaps, is about the twenty million investment that you are undertaking to address the changing needs of customers. Eli kuinka paljon käyttökustannukset tulevat kasvamaan näiden toimenpiteiden vuoksi vuosina 2026 ja 2027?
So, basically, let's put it this way: the twenty million is a collection of investments, already made and coming. It includes, for example, the Medhelp investment that you see directly from our balance sheet. And then it is a further pipeline that we are doing. So I think that the proper view is, once again, to examine our tangible assets on the balance sheet, see the increases there, and in our depreciation and amortization. I've said that the amortizations are a three to five-year period depending on the asset we are generating, so then you can from there evaluate their opex impact coming into the future. Amortisation impact coming there in the future, then if we take a look on the total opex, obviously these investments wouldn't be investments unless they improve our revenue or reduce our cost base, and all of these are positive investments as such. Of course, then the quality improvement is an important factor and so on, but in the end, the idea of investment is to contribute to our profitability in the future.
Thanks. Then, this second question is on the acquisition: how confident are you actually of its approval from the market authority, given it consolidates the market quite a lot?
Of course, we know. It is not in our hands, but maybe we can say that we made a very thorough analysis on the competitive landscape and what type of overlaps. We have based on different experts and sources, and we are very confident in our plan. But then again, it's not in our hands; it's the authority that makes the call.
Yes, I think that we have explained it thoroughly, and of course. If you want to make your own assessment, it is really easy to look at the market dynamics; you will see that even by doubling the revenue, we will be number two in the market. There wouldn't probably start with number two. So, from that perspective, of course, when you look at the total market process, you can evaluate it yourself. We have confidence, and we are confident.
And that specific reason was one of the drivers for us to start. We invest in our market share, as we saw that our market share was below average. Indeed, dental services are a very good complement to our existing services, and there we have room to grow, as Juuso explained in market share numbers.
Okei, thanks, that's all from me.
Okay, I believe we don't have any further questions from the frontline, but we will now take one from the audience.
Ronnie Burnham from Inderes, hi. Maybe about the insurance customers, the growth rate still declined here. Hieman, ja näette, että kysyntä ei ole yhtä vahvaa kuin aiemmin, joten mikä tämän taustalla on? Mielestäni se meni tummanvihreästä vaaleampaan vihreään.
Let's take a couple of steps back, first of all, to discuss the insurance. Coverage continues to grow, which is positive, so the underlying elements for growth are strong for the future. Then, as equally, now insurance companies with the health insurances. They have been struggling with the profitability, and they have implemented certain kind of steering mechanisms which Juuso alluded to as gates and guard rails in how they are then sort of allowing services to guiding services for their customers, and all in all, even though we can be pleased with our own progress and sort of success in gaining market. Here, the overall market reacts to a couple of years of very high morbidity and certain types of services, short of gain through insurances, and this held true of acquisition and combination, which led to a somewhat flat development during the first part of the year, and then recovery in the second.
Alright, then about the public market. You have there the yellow or flat demand, and you mention that you see some positive signs there, also some clear possible negative drivers in 2026.
I think that in total, the difficulty with the public sector is to predict it at the moment. I think that I've been saying for three years here. Quite many times saying that now it opens up and at the same time. It has not opened up; there are so many things that are not in our hands, and the predictability makes it a bit difficult. So we have positive signals; you may have seen us winning a tender process with Pohde in December with a positive revenue impact, and we are winning contracts, but at the same time, wellbeing services counties are polarizing at the moment. Ja taas, kuten Pirkanmaa, joka meni suureen ulkoistukseen, jonka valitettavasti Pihlajalinna voitti, ja jotka ovat valmiita toteuttamaan edistyksellisiä toimenpiteitä yhdessä julkisen ja yksityisen sektorin kanssa, ja sitten samanaikaisesti on niitä, jotka ovat edelleen hyvin varovaisia, ja miten tuo dynamiikka kehittyy, on yksinkertaisesti vaikea ennustaa, mutta olemme kokonaisuutena positiivisia. The total market is opening up and we are confident that it will happen, but putting a timeline on that one is the reason why it's on yellow.
And back to your point, is there a downside? We are starting from very low demand and very passive buying behaviour. So it's quite difficult to see further downside in this business.
Alright, then one more about the occupational healthcare. You emphasized the post-cyclical nature, and given that Finnish unemployment increased across the board last year, and you also mention that you anticipate growing connected employees, so maybe tell us a little bit about how much the growth is in your own control versus the macro, and maybe about your sales pipeline at the moment.
Well, if we start from the dynamics and their cyclical nature, there's a lag in how we see the numbers against our actions specifically in this segment; and I'm pleased with the progress of our program, as our win rates have been improving already during Q4. Q4, Laurén, the team, and the commercial team have been doing a good job. Mihin emme voi niin paljoa vaikuttaa, on käyttötiheys ja palveluiden laajuus, jotka sitten seuraavat enemmän tämän syklistä luonnetta, ja nyt yritykset ovat olleet säästötilassa. They are also in a situation where there is a great supply of employees in almost all industries, so they are not as much under pressure to improve benefits for their employees, and this is cyclical, and we have seen this. This happens many times, and when things turn around, this will also turn, so a lot of this is in our own hands, specifically when we think about the number of connected employees and the use of services, which is more on the corporate side and more cyclical, right.
Thank you, now further questions.
Let's take a couple of steps back, first of all, to insurance. Rony, we still have a couple of minutes, so I'm going to be a bit selective on the questions that we have received from the webcast, maybe. Let's talk a little bit about their drivers and the dynamics in healthcare services, could we please open up a little bit the drivers of the high profitability in the current healthcare services segment, and is that improvement sustainable in the longer term?
Now we need to split that into two different components: is the improvement sustainable, meaning can we improve quarter by quarter or year over year, like we did from Q4 2024 to Q4 2025, bearing in mind that in Q4 2024, we had in the underlying numbers the one-time items or the one-time bonuses that were referred to earlier, and that makes the improvements slightly better looking than they are in real life; however, on an absolute level, we are in a positive place. We have a huge operating leverage from that perspective when we get back on growth. When we get the yields on our occupational health project, that one will contribute to our profitability also, so there are two different answers, but the operating leverage. IT is the key when you are looking to the future; we have much to gain in this segment.
And as it is, a darling in the presentation and comments. Exactly as shared, we have been able to improve profitability against a lower revenue line. Very, very much operating leverage. IT has been improving, strengthening the efficiencies there, so that will then yield improving results once we get the revenue line in order, that's very, very clear and in that sense. IT is sustainable, again coming back to the fact that underlying megatrends are positive for demand of healthcare services.
Sitten lopuksi muutama sana M&A-kentästä: näetkö aktiivisuutta meneillään olevien transaktioiden lisäksi ja mitkä ovat houkuttelevimmat segmentit, joita tällä hetkellä tarkastelemme?
Well, if you start and we'd like to comment, I think the M&A market activity has been gradually increasing throughout 2025. It was very low in 2023 and 2024, maybe especially in 2024, and now we see that the market starts to be active. You can view it from different angles; there's your activity in Helsinki. There's transactions happening. Throughout Nordic and Europe, little by little, a market starts to form. Tietenkin sitten voi alkaa poimia, mitä ovat ne arvoa luovat mahdollisuudet, joita haluaa hyödyntää. We have been continuously pursuing our agenda, and we have a selective agenda in portfolio as well; we obviously have Hohde, which will hopefully close during this year, and then we have stated that in Sweden, for example, gaining scale and efficiency would make sense, so that has been another area we have highlighted that we could look at, and obviously, in healthcare services. We have always been checking out small bolt-ons that would complement our white spots, like we did in ophthalmology when we acquired Pilke in December.
Thanks. With that, any last words before we close the webcast, Ville?
So again, great quality, great efficiency, great profitability, market under pressure, underlying trends supporting long-term growth with a sustainable improvement agenda with us. So, looking positively forward for 2026 and specifically then for FY27.
Thanks with that have a great rest of the day and upcoming weekend. Thanks for joining.
Thank you.
Kiitos.



















